Alpha-lipoic acid modifies oxidative stress parameters in sickle cell trait subjects and sickle cell patients

Summary Background & aims Oxidative stress plays a crucial role in the sickle cell disease. Alpha-lipoic acid (ALA) is a potent antioxidant that is employed in the treatment of several diseases. The objective of this study was to test the ALA effect in the sickle cell disease (SCD) treatment. Me...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nutrition (Edinburgh, Scotland) Scotland), 2009-04, Vol.28 (2), p.192-197
Main Authors: Martins, Vanessa D, Manfredini, Vanusa, Peralba, Maria C.R, Benfato, Mara S
Format: Article
Language:English
Subjects:
Adult
Anemia, Sickle Cell - metabolism
Anemias. Hemoglobinopathies
Antioxidants - pharmacology
Biological and medical sciences
Biomarkers - blood
Catalase - blood
Catalase - drug effects
Dietary Supplements
Diseases of red blood cells
Feeding. Feeding behavior
Female
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Gastroenterology and Hepatology
Glutathione Peroxidase - blood
Glutathione Peroxidase - drug effects
Hematologic and hematopoietic diseases
Humans
Lipoic acid
Male
Malondialdehyde - blood
Medical sciences
Nutrition
Oxidative stress
Oxidative Stress - drug effects
Proteins - drug effects
Sickle cell disease
Sickle Cell Trait - metabolism
Superoxide Dismutase - blood
Superoxide Dismutase - drug effects
Thioctic Acid - pharmacology
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background & aims Oxidative stress plays a crucial role in the sickle cell disease. Alpha-lipoic acid (ALA) is a potent antioxidant that is employed in the treatment of several diseases. The objective of this study was to test the ALA effect in the sickle cell disease (SCD) treatment. Methods Sixty subjects were selected and divided into groups according to the hemoglobin profile: AA (normal), AS (SCD trait subject) and SS (SCD patient). Patients were randomized into a placebo-controlled trial and treated with either ALA (200 mg) or vehicle. Blood samples were collected before supplementation and after 3 months of treatment. Catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) activities and total antioxidant status (TAS) were evaluated as measure of antioxidant defense. Lipid and protein damages were quantified by malondialdehyde (MDA) and carbonyl assays, respectively. Results CAT activity significantly increased in the AS group after ALA treatment and GPx activity presented significant decrease in all groups. SOD activity was not different in any group. Data on MDA and carbonyl levels showed significant reduction in the AA group with ALA treatment. TAS decreased in the same group. Conclusion ALA treatment protected AA individuals from oxidative damage to lipids and proteins. In SCD subjects, the dose applied was not effective to prevent the oxidative damage.
ISSN:0261-5614
1532-1983
DOI:10.1016/j.clnu.2009.01.017